Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, Saar Gill|Journal of Clinical Investigation|2016Cited by 554
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Marco Ruella, Yong Gu Lee et al.|Cancer Discovery|2020Cited by 297
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A. Reiss, Yara Abdou, Sabrina Ceeraz DeLong et al.|Nature Medicine|2025Cited by 189
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119